Heptaplatin Sunpla

Base Information

• Chemical Name: Heptaplatin Sunpla
• CAS No.: 146665-77-2
• Molecular Formula: C11H20N2O6Pt
• Molecular Weight: 471.37
• UNII: 1352HON1DH
• DSSTox Substance ID: DTXSID20932874
• Wikidata: Q27251475
• Mol file: 146665-77-2.mol

Synonyms:Heptaplatin Sunpla;[SP-4-2-[4R-(2a,4a,5b)]]-[2-(1-Methylethyl)-1,3-dioxolane-4,5-dimethanamine-N,N'][propanedioato(2-)-O,O']-platinum;cis-((4R,5R)-2-Isopropyl-1,3-dioxolane-4,5-bis(methylamine)-N,N')(malonato(2-)-O,O')platinum;Eptaplatin;Sunpla;Eptaplatin [INN];EPTAPLATIN [MART.];EPTAPLATIN [WHO-DD];SCHEMBL1650093;DTXSID20932874;BCP18184;MFCD00931412;AKOS015896319;LS-117773;NSC644591 NSCD644591 SKI2053R;Q27251475;[(4R,5R)-5-(Aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate;Platinum(2+) propanedioate--[2-(propan-2-yl)-1,3-dioxolane-4,5-diyl]dimethanamine (1/1/1)

Chemical Property of Heptaplatin Sunpla

Chemical Property:

• Appearance/Colour: white crystalline powder
• Vapor Pressure: 0.0115mmHg at 25°C
• Melting Point: 43-49 °C
• Boiling Point: 261.5 °C at 760 mmHg
• Flash Point: 114 °C
• Storage Temp.: Refrigerator, Under Inert Atmosphere
• Solubility.: DMSO (Slightly), Water (Slightly, Heated)
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 3
• Exact Mass: 471.096931
• Heavy Atom Count: 20
• Complexity: 201

Purity/Quality:

99% ^*data from raw suppliers

Eptaplatin ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC(C)C1OC(C(O1)CN)CN.C(C(=O)[O-])C(=O)[O-].[Pt+2]
• Isomeric SMILES: CC(C)C1O[C@@H]([C@H](O1)CN)CN.C(C(=O)[O-])C(=O)[O-].[Pt+2]
• Description: SKI-2053R was launched in Korea for the treatment of patients with advanced gastric adenocarcinoma. It is a third generation platinum complex alkylating agent with less nephrotoxicity than cisplatin. In in vitro experiments, SKI-2053R was highly active against various cell lines including cisplatinresistant tumor cell lines. In mice implanted with L1210 cells, SKI-2053R showed activity comparable or superior to cisplatin or carboplatin. In mice implanted s.c. with human tumor xenograft KATO III (stomach adenocarcinoma), SKI-2053R achieved growth-inhibition rates comparable with those of cisplatin. General pharmacological studies in animals did not display any severe adverse effects on the different systems at antitumour doses. Pharmacokinetic studies after a single iv administration in rats demonstrated that the compound was extensively and rapidly distributed into all tissues except the CNS. In patients with unresectable or metastatic gastric adenocarcinoma, SKI-2053R was active without significant hematological toxicity. Phase III trials with SKI-2053R are currently ongoing for the treatment of various other cancers including lung, head and neck.
• Uses: A coordination compound for treatment of cervix cancer.